Researchers discover a potential chemotherapy agent that causes cancer cells to release signals similar to those released by infected cells, triggering an immune response. This finding could lead to a new approach in cancer treatment, using lower doses of chemotherapy drugs to recruit the immune system as an ally.
Researchers at Weill Cornell Medicine have identified the FOXJ1 gene as a key player in chemotherapy resistance in prostate cancer. The study found that increased FOXJ1 levels in tumors can make cancer cells less responsive to taxane chemotherapy, leading to poorer outcomes for patients.
The Alliance for Clinical Trials in Oncology is spotlighting new trials for colorectal cancer in March, focusing on early detection methods and treatments for treatment delays and loss of appetite. The trials aim to improve patient outcomes, with several enrolling patients with newly diagnosed colon or rectal cancer.
Researchers analyzed 15-year data from a clinical trial, finding that 70% of patients remained alive and 42% were considered cured after treatment. Cure modeling estimated the overall cure rate at 42% of treated patients.
A new study shows that exercise during chemotherapy measurably improves quality of life for women with breast cancer, with benefits consistent across physical, emotional and mental health domains. The findings support existing clinical guidelines and provide clarity on the effectiveness of exercise interventions during treatment.
A Singapore study reveals that a specific gene called SERPINE1 drives resistance to chemotherapy and cancer spread in colorectal cancer patients. The findings also identify a molecular signature called RESIST-M, which can predict poorer survival and higher relapse risk, supporting earlier intervention and more targeted follow-up care.
A new study published in the Journal of the National Comprehensive Cancer Network (JNCCN) identifies significant long-term health risks among testicular cancer survivors treated with contemporary chemotherapy regimens. Researchers found that survivors treated with etoposide and cisplatin (EPx4) had higher odds of renal impairment, hear...
Researchers identify PAK1 as a key player in colorectal cancer progression through its ability to stabilize mRNA of oncogenic factors. Targeting PAK1 inhibits proliferation, migration, and invasion, promoting the degradation of these transcripts and sensitizing tumors to standard-of-care treatments.
Researchers developed a new computational approach to predict chemotherapy response in triple-negative breast cancer, outperforming current methods. The TmS biomarker accurately sorts patients into those with favorable or poor prognosis, highlighting its potential as an effective starting point for patient stratification.
A new study shows that pancreatic cancer cells' ability to detect the extracellular matrix determines their growth rate and response to chemotherapy. The researchers found that cells detecting ECM have low autophagy levels and high growth rates, while those farther away from ECM have high autophagy levels and can survive chemotherapy.
Researchers at Sylvester Cancer Institute have identified a potential workaround for chemotherapy resistance by blocking a key protein. The study aims to teach lymphoma patients practical tools to manage stress and improve their daily quality of life through the SMART 3RP Lymphoma study. Meanwhile, the institute is expanding cancer dis...
The American Society of Hematology released guidelines for frontline and relapsed/refractory management of acute lymphoblastic leukemia (ALL) in adolescents and young adults (AYAs), outlining optimal approaches to treating high-risk patient populations. The guidelines highlight the need for additional research on immunotherapies and tr...
Researchers used Caenorhabditis elegans to model chemotherapy-induced neurological dysfunction and tested two compounds for improved recovery. Both sildenafil citrate and Resveramorph-3 significantly reduced seizure-like behaviors and duration, suggesting their potential as therapeutic candidates.
A new study suggests blocking key protein p300 can create novel form of cellular stress in cancer cells, re-sensitizing chemo-resistant tumors. Cells produce proteins even with damaged DNA, leading to toxic buildup and stress inside the cell's internal quality-control system.
A rare case of hyperammonemic encephalopathy caused by 5-fluorouracil (5-FU) chemotherapy has been reported, highlighting the importance of monitoring neurological symptoms in patients receiving 5-FU. The patient's symptoms resolved after stopping 5-FU and administering lactulose and intravenous fluids.
Researchers found GXYLT2 promotes malignant phenotypes in diffuse-type gastric cancer cells, driving tumor progression through Wnt/β-catenin signaling. Targeting GXYLT2 or its downstream axis may provide a novel strategy for improving molecular stratification and therapeutic intervention in gastric cancer.
A study led by researchers from the Germans Trias i Pujol Research Institute has identified PARG as a new target to enhance chemotherapy in colorectal cancer. Inhibition of PARG significantly increases the cytotoxic effect of chemotherapy, leading to enhanced cell death and apoptosis in different colorectal cancer models.
A new Phase II trial will examine whether giving chemotherapy or chemotherapy combined with immunotherapy before surgery can improve survival compared to surgery alone. The trial aims to identify a treatment that will help patients live longer without the cancer returning.
Research reveals that chemotherapy alters the gut microbiota, producing indole-3-propionic acid, which travels to the bone marrow and rewires immune cell production. This leads to a metastasis-refractory state in preclinical models and improved survival outcomes in patients with colorectal cancer.
A study from Flinders University found that patients with progressive disease, which describes the way cancer grows, have varying survival rates depending on whether their existing tumours re-grow or new ones appear. Understanding this progression can help doctors make better decisions about future treatment strategies.
A new clinical trial, PAGODA, seeks to minimize treatment interruptions and help patients complete their chemotherapy as planned. The trial will test a structured plan to guide doctors in making small, proactive changes to chemotherapy doses to prevent treatment delays.
Researchers found that pitavastatin directly inhibits the anti-apoptotic protein Mcl-1, a key driver of survival and resistance in TNBC cells. The study showed pitavastatin effectively eliminates cancer stem-like cell populations and reduces tumor growth, angiogenesis, and lung metastasis.
Researchers create a novel mathematical framework to control biological noise, enabling precise single-cell control. The 'Noise Robust Perfect Adaptation' technology suppresses stochastic fluctuations while maintaining stable average behavior, with promising applications in cancer therapy and synthetic biology.
A recent study reveals how the C/G fusion hijacks DNA methylation and chromatin architecture to drive aggressive acute myeloid leukemia in children. The study identifies DNMT3B as a critical effector of the fusion, highlighting its potential as a therapeutic target.
A study published in EMBO Molecular Medicine has identified a combination of statins and phenothiazines that shows promise in treating aggressive neuroblastoma. The drug combination was found to impede tumour growth and improve survival rates in laboratory trials with mice.
Researchers will investigate how HIV and cancer drugs damage brain cells over time, identifying potential early biomarkers of neurotoxicity. They will use human brain organoids grown in the lab to mimic brain physiology.
Researchers at the University of Geneva have created a laboratory platform to rapidly evaluate the toxicity of new cancer treatments using human tissue-derived cell clusters. This approach allows for safer evaluation and could lead to personalized treatment options.
Researchers discovered glioblastoma cells use PRDM9 to survive chemotherapy and regrow tumors. By blocking PRDM9 or cutting off cholesterol supply, persister cells can be wiped out, improving survival in mice. This breakthrough offers new strategies for treating the deadliest brain cancer.
Researchers found that patients who received immunochemotherapy before 3:00 pm experienced significantly longer progression-free survival and overall survival compared to those treated later. Earlier administration of immunotherapy was also associated with lower risks of cancer progression and death.
A new study developed an antibody that blocks several ways TNBC cells survive, grow, and evade the immune system. The antibody suppressed primary tumor growth and reenergized cancer-fighting immune cells, including T-cells and macrophages, in preclinical models.
Australian researchers have discovered a drug combination that can bypass the cellular defenses developed by neuroblastoma tumors, making it more effective against relapsed cases. The combination reduces tumor growth and extends survival time compared to standard treatment alone.
Researchers found that FOLFIRINOX improved progression-free and overall survival in patients with advanced biliary tract cancer. The treatment may offer a benefit as a second-line option after first-line chemotherapy failure, but toxicity remains a concern.
Researchers discover IRE1α pathway in immune cells triggers inflammation and nerve damage after chemotherapy, providing a potential target for prevention and treatment. Biomarkers may help identify patients at risk of developing chemotherapy-induced peripheral neuropathy.
The American Society for Radiation Oncology (ASTRO) has published its first clinical guideline on radiation therapy for gastric cancer. The guidelines provide evidence-based recommendations for the role of radiation therapy in multidisciplinary care, including patient selection, integration with systemic therapy and treatment delivery.
A clinical trial led by the University of Oklahoma Health Stephenson Cancer Center has shown promising results with a new drug combination targeting metastatic colorectal cancer in patients with ATM-deficient tumors. The treatment, combining alnodesertib and irinotecan, showed substantial reductions in cancer size in these patients.
Experts warn that new drugs for advanced breast cancer are unaffordable and may lead to unequal treatment access worldwide. The consensus panel recommended prioritizing most effective treatments and using next-generation sequencing for personalized medicine.
A new study from the University of South Australia found that up to 50% of patients are missing out on vital foot care after chemotherapy, despite irreversible nerve damage being a common side effect. Podiatry services can prevent falls, ulcerations, pain, and improve mobility in cancer survivors with CIPN.
A study of 168 patients with ampullary adenocarcinoma reveals that the pancreatobiliary signature and blood vessel invasion are independent indicators of poor outcomes. Tumor deposits are identified as a crucial context-dependent biomarker, predicting who benefits from adjuvant chemotherapy.
The DEFEND study aims to assess whether virtual exercise sessions can be successfully delivered to patients with cancer receiving chemotherapy. Researchers will evaluate the impact on physical function, fatigue, and disability.
Scientists re-engineered a common chemotherapy drug to make it more soluble and effective, targeting cancer cells while leaving healthy tissues unharmed. The new nanomedicine significantly extended survival in animal models of leukemia, showing promise for improved cancer treatment.
A study by Wake Forest University School of Medicine reveals that a stress response in immune cells contributes to chemotherapy-induced nerve damage. By blocking this pathway, researchers aim to develop new treatments to protect cancer patients from debilitating side effects.
A team of researchers identified a unique protein signature that can predict which patients are likely to resist standard therapies, paving the way for personalized treatments. By blocking a specific transporter system, they made tumors more sensitive to treatment, suggesting a promising new avenue for treating colorectal cancer.
Researchers suggest chemotherapy drugs may be responsible for 'chemo brain' symptoms, citing reduced lymphatic vessel growth and impaired cognitive function. The study highlights the need to consider long-term neurological side effects of cancer treatment on quality of life.
A new strategy uses self-assembling peptide nanotubes to deliver doxorubicin into the nucleus of chemotherapy-resistant cancer cells, preserving antitumor activity. The approach utilizes cyclic peptides to stack and self-assemble into hollow cylindrical structures that facilitate drug delivery.
Research found that inflammatory markers are linked to different aspects of cancer-related fatigue, with some effects persisting after treatment. The study suggests targeting inflammation for developing treatments to alleviate this debilitating symptom.
A topical formulation has been shown to reduce the incidence of hand-foot neuropathy in cancer patients undergoing chemotherapy, improving quality of life. The cream, developed at UMH, acts directly on neurosensory pain receptors, reducing hypersensitivity and tolerance to chemotherapy.
A diet rich in cysteine has been shown to activate immune cells that help regenerate intestinal tissue, potentially offering a new way to heal tissue damage from radiation or chemotherapy treatment. The researchers found that cysteine initiates a chain of events leading to the activation of CD8 T cells, which produce cytokines like IL-...
A large-scale population study found that oxaliplatin benefits only younger stage III patients, with no added survival benefit for those over 70. The study suggests using an age threshold to make evidence-based choices about chemotherapy.
The American Society for Radiation Oncology, American Society of Clinical Oncology, and Society of Surgical Oncology jointly published a guideline outlining when post-mastectomy radiation therapy (PMRT) is appropriate based on new evidence. PMRT reduces cancer recurrence risk in patients with node-positive disease or high-risk features.
Adult fibrosarcoma is a rare and highly aggressive malignancy requiring precise diagnosis and multimodal treatment. The case report emphasizes the need for early detection, complete surgical removal, and tailored postoperative care to improve outcomes in patients with this type of tumor.
Research reveals that chemotherapy impairs molecular and behavioral measures of the primary biological clock found in the brain. In a study on female mice, paclitaxel treatment disrupted circadian rhythm-related gene expression and behavioral adaptations to light challenges.
Researchers at MD Anderson have made significant advancements in treating kidney cancer, including the use of metastasis-directed targeted radiation therapy to delay systemic treatments. Additionally, preliminary data from an ELI-002 vaccine trial showed promise in delaying relapse of KRAS-mutated pancreatic and colorectal cancers.
A Mayo Clinic study shows that a shorter, less intense course of radiation and chemotherapy after minimally invasive surgery significantly reduces treatment-related side effects while maintaining high cure rates. The findings apply to intermediate-risk patients, with slightly better disease control in high-risk patients.
Researchers at Michigan State University have developed a hydrogel that can be applied to the scalp before chemotherapy treatment, helping to restrict blood flow and prevent hair loss. The temperature-responsive gel is designed to be easily washed off once treatment is complete.
Forskolin, a natural compound, significantly improves treatment outcomes for KMT2A-r AML by directly stopping leukaemia cell growth and enhancing chemotherapy effectiveness. Forskolin blocks P-glycoprotein 1, allowing more chemotherapy drugs to enter leukaemia cells, making treatments more potent.
A 36-year-old woman was diagnosed with non-gestational ovarian choriocarcinoma, a rare and aggressive tumor that shares symptoms with pregnancy. She received chemotherapy and showed complete response to treatment.
Cancer cells with abundant circular DNA elements (ecDNA) carrying oncogenes like MYCN are resistant to chemotherapy. Combining standard chemotherapy with a secondary therapy targeting these senescent cells leads to improved outcomes in mouse models of neuroblastoma and medulloblastoma.
A groundbreaking cancer drug, KCL-HO-1i, has shown promise in making chemotherapy-resistant cancers more responsive to therapy by targeting a key defence mechanism used by tumours. In preclinical models, the drug has already demonstrated effectiveness in laboratory tests using mouse models of breast cancer.
Researchers found that Fen1 protein improves cell tolerance to alovudine by counteracting the toxic effect of 53BP1. This discovery promises new cancer treatments and biomarkers for cancerous cells with Fen1 deficiency.
This book presents cutting-edge approaches to combat cancer, including exosomal delivery systems, CRISPR/Cas9 gene editing, and immunotoxin therapy. Natural compounds are also examined for their anticancer potential.